Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (4)

2024

  1. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  2. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  3. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1

2019

  1. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence

    Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1108-1119